Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 8/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13476251 | 0.91 | ABCB1 (0.48) | ABCB1KCNA5IDO1ABCC9FUCA1 | |
| SCHEMBL2889446 | 0.87 | ABCB1 (0.51) | ABCB1KCNA5IDO1ABCC9FUCA1 | |
| SCHEMBL2007814 | 0.87 | ABCB1 (0.51) | ABCB1KCNA5IDO1ABCC9FUCA1 | |
| SCHEMBL2010363 | 0.85 | ABCB1 (0.47) | ABCB1KCNA5IDO1ABCC9FUCA1 | |
| SCHEMBL2890974 | 0.85 | ABCB1 (0.47) | ABCB1KCNA5IDO1ABCC9FUCA1 | |
| SCHEMBL7253762 | 0.85 | ABCB1 (0.53) | ABCB1KCNA5IDO1FUCA1 | |
| SCHEMBL13476129 | 0.84 | ABCB1 (0.48) | ABCB1KCNA5IDO1ABCC9FUCA1 | |
| SCHEMBL2007669 | 0.84 | ABCB1 (0.48) | ABCB1KCNA5IDO1ABCC9 | |
| SCHEMBL2888894 | 0.84 | ABCB1 (0.48) | ABCB1KCNA5IDO1ABCC9 | |
| SCHEMBL2009066 | 0.83 | ABCB1 (0.44) | ABCB1KCNA5IDO1ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | ABCB1 647/4885KCNA5 101/4885IDO1 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.